Skip to content
Screener

Aurinia Pharmaceuticals AUPH Q2 2025 earnings

Reported July 31, 2025 · Before market open

Revenue$70.0MBeat by $2.3M
EPS$0.16Miss by $0.01
Revenue estimate$67.7M
EPS estimate$0.17

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$83.6M
EPS estimate$0.21

Financials

Q2 2025

Income statement

See full
Revenue$70.0M+22.4%
Gross profit$62.9M+30.3%
Operating income$20.1M+1,427%
Net income$21.5M+2,880%
EPS (diluted)$0.16+1,500%

Balance sheet

See full
Cash & equivalents$53.0M+58.7%
Total debt$98.0M-1.9%
Total equity$335.3M-8.0%
Total assets$502.6M-4.0%

Cash flow

See full
Operating cash flow$44.2M+179%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.09B+33.2%
Enterprise value$1.13B+28.2%
P/E17.9×—
P/S4.2×+0.2×

Profitability

See full
Gross margin89.5%+3.4pp
Operating margin20%+12.5pp
Net margin23.3%+15.4pp

Returns & leverage

See full
Return on equity17.3%+12.1pp
Debt / equity0.3×0.0×
Current ratio5.2×-0.1×

Segments

By geography

See full
U.S.$66.0M—
Japan$4.8M—

By product

See full
License, collaboration and royalty revenue$3.4M+58.7%

FAQ

When did Aurinia Pharmaceuticals report Q2 2025 earnings?
Aurinia Pharmaceuticals (AUPH) reported Q2 2025 earnings on July 31, 2025 before market open.
What were Aurinia Pharmaceuticals's Q2 2025 revenue and EPS?
Aurinia Pharmaceuticals reported revenue of $70.0M and eps of $0.16 for Q2 2025.
Did Aurinia Pharmaceuticals beat estimates in Q2 2025?
Revenue beat the consensus estimate of $67.7M by $2.3M. EPS missed the consensus estimate of $0.17 by $0.01.
How did Aurinia Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 22.4% from $57.2M a year earlier and eps grew 700.0% from $0.02.
Where can I find Aurinia Pharmaceuticals's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001600620-25-000090) and the 10-Q periodic report (0001600620-25-000092) directly on SEC EDGAR. The filing index links above go to sec.gov.